A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2015
Price : $35 *
At a glance
- Drugs Cibinetide (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARAND
- 15 Dec 2014 Results published in North Shore-Long Island Jewish Health System media release.
- 15 Dec 2014 Results have been published in Molecular Medicine, according to a North Shore-Long Island Jewish Health System media release.
- 15 Dec 2014 Status changed from recruiting to completed, according to a media release reporting results have been published.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History